StemCyte, Inc. Launches New Website

COVINA, Calif., Dec. 7, 2010 /PRNewswire/ -- California-based StemCyte, Inc. announces the launching of its new website, www.StemCyte.com, a comprehensive resource on cord blood banking and its transplant and research initiatives. In an effort to provide the most comprehensive source of cord blood banking information and education online, StemCyte's new website includes extensive information for customers, physicians, and the general public on the lifesaving medical resource of umbilical cord blood stem cells as well as the potential for regenerative medicine.

After robust feedback from physicians, clients, researchers and expecting parents during the past year, StemCyte reconstructed its website to provide the quickest and most efficient educational guide to learning about the science and promise of cord blood banking. Free information kits and educational videos are also available to interested parties at www.StemCyte.com.

"As one of the world's preeminent cord blood banks and biotherapy companies, we are pleased to offer this critical information and communication tool to our global audience," said Calvin Cole, StemCyte's President, North America. "We are committed to making available timely and accurate information regarding public and private cord blood banking options, updates on existing therapies and the latest information on cutting-edge biotherapy research."

This website represents StemCyte's latest effort to enhance awareness regarding the science and promise of umbilical cord blood banking and related medical research.

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,300 cord blood products for over 70 life-threatening diseases to over 200 leading worldwide transplant centers. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and supporting the developments of trials investigating regenerative spinal cord therapies. They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units. Its headquarters are located in Covina, Ca. and Ewing, NJ. To learn more visit www.StemCyte.com.

SOURCE StemCyte, Inc.